Stories and Viewpoints

Discover Viatris: Delivering a Diverse and Robust Portfolio to Our Customers in Developed Markets

Join us as we explore the gears that power our business model in our ongoing series #DiscoverViatris.

July 21, 2021


At Viatris, we are reimagining healthcare to empower people worldwide to live healthier at every stage of life. Our business model is fueled in part by our deep-market experience around the world including in our Developed Markets segment, which consists of North America and Europe. Learn five things about our Developed Markets segment:


1 North America, made up of the U.S. and Canada, continues to be a strong business within Viatris, with a strategically focused field force of ~400 and a diverse portfolio of more than 700 best-in-class products, including brands, complex generics and biosimilars, and generics.


2 In North America, we supply medicines for patients spanning a broad range of major therapeutic areas, spread across multiple technologies and dosage forms. We have a differentiated portfolio, and in the U.S. continue to be a leader in the retail pharma market ranking No. 2 in value, with nearly half of our generic products ranked No. 1 or No. 2 in terms of value.1 We have also made significant investments in science to support our robust pipeline.


3 Our Europe region is divided into three main areas: Southern Europe, Central, and Eastern Europe, and Northern and Western Europe. We have a sales force of more than 3,000 colleagues working in more than 35 countries building longstanding relationships that have allowed us to be a partner of choice to our customers.


4 Our product portfolio in Europe includes more than 1,400 medicines across a broad range of therapeutic areas. We have one of the industry’s largest and most diverse biosimilar portfolios with a presence in oncology, immunology, and diabetes. We are also a key player across the region in the treatment of thrombosis through our acquisition of Aspen’s thrombosis portfolio, further complementing and expanding our complex injectables offering and presence in hospitals.


5 With a proven track record of delivering high-quality medicines to customers in both North America and Europe, our workforce is well-positioned to build on our established partnerships and brand equity to be a leader in bringing medicines to patients when and where they need them.


Learn more about our Developed Markets segment by exploring highlights from our business in Europe and North America in the infographics below:




1 IQVIA MIDAS and Regulatory Insights MAT ending 9/20 – refers to generic market

You may also like
  • Share this: